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Abstract
Inappropriate kinase expression and subsequent promiscuous activity defines the transformation of 
many solid tumors including renal cell carcinoma (RCC). Thus, the expression of novel tumor-
associated kinases has the potential to dramatically shape tumor cell behavior. Further, identifying 
tumor-associated kinases can lend insight into patterns of tumor growth and characteristics. Here, 
we report the identification of Ror2, a new tumor-associated kinase in RCC cell lines and primary 
tumors. Ror2 is an orphan receptor tyrosine kinase with physiological expression normally seen in 
the embryonic kidney. However, in RCC, Ror2 expression correlated with expression of genes 
involved at the extracellular matrix, including Twist and matrix metalloprotease-2 (MMP2). 
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Expression of MMP2 in RCC cells was suppressed by Ror2 knockdown, placing Ror2 as a 
mediator of MMP2 regulation in RCC and a potential regulator of extracellular matrix remodeling. 
The suppression of Ror2 not only inhibited cell migration, but also inhibited anchorage 
independent growth in soft agar and growth in an orthotopic xenograft model. These findings 
suggest a novel pathway of tumor-promoting activity by Ror2 within a subset of renal carcinomas, 
with significant implications for unraveling the tumorigenesis of RCC.
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INTRODUCTION
Although tumor biology is tightly linked in many ways to the processes of embryonic 
development, a largely untapped area of solid tumor oncology is the specific examination of 
growth promoting pathways that are unique and critical to early developmental patterning. 
One such signaling pathway, Wnt, is a process common to both developmental and 
malignant states (Coombs et al., 2008). The identification of these signaling molecules that 
play a physiologic role in early developmental processes, with potential to promote tumor 
growth or other pathologic characteristics in the adult, provides an opportunity to define 
biological cause for various tumor attributes (Nakagawara, 2001). Further, identifying such 
molecules with restricted tissue expression in the adult organism provides a valuable chance 
for diagnostic or therapeutic implementation.
Epithelial cells require modulations in diverse signaling pathways to support the numerous 
cellular changes necessary to attain metastatic potential. Specifically, receptor tyrosine 
kinase (RTK) activation causes deregulated signaling and can defines tumor subsets across a 
broad spectrum of tumors (Stommel et al., 2007). Such variations in kinase activation have 
the potential to facilitate the cellular adaptations that determine patterns of tumor growth and 
can provide tremendous insight into the cell biology of that transformative process (de 
Castro-Carpeno et al., 2008; De Luca et al., 2008).
Among the cellular changes associated with tumor progression is tissue remodeling 
compatible with the extensive migration necessary for the progression of metastatic disease. 
This cellular transition is shared by the developmentally regulated processes which direct 
limb formation or other tissue patterning events. Tissue remodeling is driven by matrix 
metalloproteases (MMPs), a family of enzymes that degrade the extracellular matrix (ECM), 
and is integral to both normal tissue development and cancer progression (Liotta & Kohn, 
2001). These processes signal cellular alterations that allow single cells to detach from the 
epithelial tumor collective, interrupting cell-cell junctions and increasing cell motility. 
Taken together, this highly coordinated process is critical for the lethality of most epithelial 
malignancies.
One such lethal epithelial malignancy, renal cell carcinoma (RCC), affects over 40,000 
individuals in the US annually (Cancer Facts and Figures, (2008). Nearly a third of these 
patients present with unresectable or metastatic disease, for which antiangiogenic therapies 
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are the mainstay of therapy (Cowey & Rathmell, 2008; Rathmell et al., 2005). RCC 
describes a group of histologically and genetically distinct neoplasms, the most common 
being clear cell RCC, with the remainder being papillary and chromophobe RCCs (Linehan 
et al., 2003). The mechanisms that promote tumor invasiveness or the acquisition of 
metastatic potential for the subtypes of RCC remain undefined.
ECM remodeling, a common step towards invasiveness, is promoted by tumor cells through 
changes in intracellular signaling and commonly acquiring characteristics of less 
differentiated cellular precursors (Liotta & Kohn, 2001). One developmentally-regulated 
pathway inappropriately activated in many epithelial tumors is Wnt protein signaling via the 
frizzled and LRP co-receptors (Atkins et al., 2004; van Amerongen et al., 2008). Here we 
report the identification of a Wnt receptor of embryonic mesenchymal origin expressed in 
RCC cell lines and tumors that defines a subgroup of human tumors with an invasive growth 
profile of gene expression. The novel receptor tyrosine kinase-like orphan receptor 2 (Ror2) 
is part of a family of orphan RTKs (Deloukas et al., 1998; Oldridge et al., 2000). Ror2 is 
characterized by an intracellular tyrosine kinase domain (Masiakowski & Carroll, 1992) and 
an extracellular Frizzled-like cysteine-rich domain (CRD), shown to act as a receptor for 
Wnt ligands (Oishi et al., 1997). Mouse Ror2 (mRor2) expression is normally observed in 
the developing heart, brain and lungs (Matsuda et al., 2001; Schwabe et al., 2004; Takeuchi 
et al., 2000; Yoda et al., 2003), with the greatest expression seen in migrating neural crest 
and mesenchymal tissues (Yoda et al., 2003). In the developing kidney, we have observed 
Ror2 expression in the migrating nests of mesenchymal cells. Further, Ror2 expression was 
identified in RCC tumors and is coordinated with invasive growth in culture. Coupled with 
the observations that Ror2 impacts expression of MMP2 and tumor cell growth in vitro and 
in vivo, this study identifies a novel developmentally regulated receptor that enhances RCC 
tumor cell growth capabilities.
RESULTS
Identification of Ror2 in renal carcinoma cells and human RCC tumors
To identify activated kinases in RCC cell lines, a phosphorylated-tyrosine kinase array was 
used to screen for kinases with a basal level of tyrosine phosphorylation in unstimulated 
RCC lysates. Tyrosine kinases expected to be activated in RCC such as the epithelial growth 
factor receptor (EGFR) were detected on the array. Among the phosphorylated-tyrosine 
kinases interrogated on the array, Ror2 was positively identified upon multiple examinations 
of the RCC cell line, 786-0 RC3, a control vector-transfected derivative of the VHL- mutant 
RCC cell line 786-0 (Figure 1A). Abundant expression of the endogenous protein in 786-0 
RC3 cells was confirmed by immunoblot analysis. Immunoprecipitation of Ror2 with 
independent antibodies confirms high protein levels and basal autophosphorylation of the 
tyrosine kinase (Supplementary Figure 1A). Upon examination of other cell lines, we 
observed Ror2 expression in the parental RCC cell line, 786-0, using two independent 
antibodies targeting Ror2, but not in the SV-40-immortalized human proximal tubule cell 
line, HKC (Supplementary Figure 1B). Additionally, we demonstrated that Ror2 expression 
was present in an unrelated RCC cell line, RCC4 2-1 (Supplementary Figure 1B) further 
signifying Ror2′s role in RCC tumorigenesis deserved further exploration.
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Ror2 is a developmentally regulated kinase, with expression primarily relegated to 
embryonic mesenchymal tissues (Yoda et al., 2003). To examine a possible role in 
malignant tissue, Ror2 mRNA expression was analyzed by RT-PCR in 19 primary human 
RCC tumors. Four representative tumor specimens are demonstrated in Figure 1B with the 
HPRT gene used as a control for RNA abundance and integrity. The band detected as Ror2 
in Figure 1B was purified and sequenced, confirming identity to the Ror2 CRD domain as 
predicted (data not shown). Overall, Ror2 transcript was detected in more than 55% of an 
unselected set of archival renal tumors (Figure 1B). Ror2 mRNA was detected even in some 
tumors of non-clear cell histology, suggesting that various genetic mechanisms may have the 
potential to promote the induction of Ror2 in renal cancers.
Detecting Ror2 expression in a malignant context prompted an evaluation of Ror2 
expression in the normal human kidney. Ror2 is well known to be expressed in developing 
tissues with expression often restricted to mesenchymal cells (Yoda et al., 2003). Consistent 
with this profile, Ror2 protein was detected in human fetal kidneys in the migrating nests of 
mesenchymal cells that give rise to the bulk of the cell types of the developing kidney 
(Figure 1C).
Ror2 protein expression is detected on tumor cells of primary human tumors
As Ror2 mRNA expression was found in RCC tumors, we asked if Ror2 can also be 
identified at the protein level. Protein expression of Ror2 was analyzed by immunostaining 
two tumors demonstrating high levels of Ror2 transcript and two Ror2 transcript-negative 
tumors (one representative Ror2 negative tumor shown). Hematoxylin and eosin (H&E) 
serial sections demonstrate the clear cell histology of each of these tumors and lack of 
significant non-tumor cell infiltration. Immunofluorescent detection of Ror2 demonstrates 
tumor cell specific expression of Ror2 protein (Figure 2). The immunofluorescence signal 
was undetectable in tumors identified as lacking Ror2 mRNA expression based on the RT-
PCR evaluation, or in the absence of Ror2 primary antibody. Nuclear stain shown from the 
same field demonstrates the presence of cellular constituents. Ror2 protein is, therefore, 
present in a subset of primary RCC tumors and can be detected specifically on the tumor 
cells of the specimen.
Ror2 expression in RCC tumors defines a tumor genetic profile of ECM genes
To analyze the role of Ror2 signaling in human RCC, an initial set of 13 human tumors were 
examined for gene expression using the 44K Agilent array platform. Tumors were classified 
as having undetectable, low, or high expression of Ror2 based on absolute Ror2 probe 
values on the array. Ror2 expression on the array was congruent with expression patterns 
observed by conventional RT-PCR. Based on these designations, a three-way analysis for 
differentially expressed targets was performed. When the 250 genes that associate most 
significantly with Ror2 expression (False Discovery Rate (FDR) < 0.07) were analyzed by 
hierarchical clustering, a subset of genes including extracellular matrix (ECM) candidates 
Twist1 and Twist2 were identified (Supplementary Figure 2). In a larger, but still highly 
significant gene cluster for association with Ror2 (FDR < 0.15), the ECM factor MMP2 was 
also identified (data not shown). Other genes identified in this significant association 
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included those linked with Wnt signaling such as catenin δ2, frizzled related protein and 
cathepsin K.
In support of these data, additional RCC tumors were analyzed and clustered based on Ror2 
expression. Independent microarray analysis was performed using the same 44K Agilent 
array platform revealing a similar set of highly coordinately regulated genes which were 
identified in all RCC histologies with a FDR < 0.045 (Figure 3A) and in clear cell with a 
FDR < 0.039 (Figure 3B). Again, Twist1 and MMP2 were found to be tightly associated 
with Ror2 expression. Altered expression for these transcripts (Twist1 and MMP2) was 
confirmed by quantitative RT-PCR of four representative tumors (Ror2 + and Ror2 -), 
confirming co-regulation (Figure 3C). Gene set analysis further supports an association 
between Ror2 expression and MMP2, identifying gene associations with the extended list of 
MMP family members and members of the Reck pathway. Additionally, in its physiologic 
role, Ror2 is tightly linked to skeletal development, thus it is intriguing to see a gene set 
reminiscent of that process associated with high statistical significance with a subset of 
human tumors of epithelial origin. An expanded listing of the members of the associated 
gene sets is shown in Figure 3D. These gene sets validate the initial gene expression study 
and support a thematic program of gene expression in these tumors associated with 
extracellular matrix remodeling. Together, these data extend a potential role for Ror2 as a 
mediator of tumor characteristics normally reserved for early and highly regulated 
developmental processes.
Ror2 expression directs MMP2 gene expression, cell migration and anchorage 
independent growth in RCC
Based on the expression array findings, we sought to explore a direct relationship between 
Ror2 expression and the expression of genes involved in ECM remodeling. Suppression of 
Ror2 protein in the 786-0 RCC cell line with two independent shRNAs targeting distinct 
regions of Ror2, in comparison to the scramble shRNA and control empty vector pRS, is 
demonstrated by immunoblot in Figure 4A. The levels of Twist1 protein were also examined 
and no change in expression was observed by immunoblot analysis (Figure 4A). This result 
suggests that Ror2 may be part of a larger program of gene expression but does not play a 
direct role in regulating Twist1 expression. Ror2-deficient cells were examined by 
quantitative RT-PCR for effects on other genes expressed as a part of the ECM phenotype. 
Transcript levels of MMP2 were highly suppressed by Ror2 shRNA (Figure 4B). Thus, Ror2 
may participate in the coordinated events involved in renal epithelial ECM remodeling by 
regulating the expression of MMP2 in tumor cells derived from this tissue.
The functional consequence of Ror2 suppression was examined in assays of tumor cell 
invasive properties, beginning with cell migration. Wound healing was measured as a means 
to quantify cellular migration because suppression of Ror2 by shRNA did not directly 
impact doubling time or viability of cultured cells (Supplementary Figure 3). We examined 
wound healing in two independent stable shRNA Ror2 knockdowns generated in 786-0 
subclones. Healing was assayed in triplicate at 0, 8, 16, and 24 hour timepoints. Cells 
lacking Ror2 expression failed to close the wound as efficiently as their isogenic 
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counterparts, scramble shRNA (data not shown) or pRS (Figure 4C), suggesting that Ror2 
may play an important role in promoting cell migration.
Another tumor cell characteristic of metastatic RCC and tumor invasiveness associated with 
the ECM is anchorage independent growth. To determine whether Ror2 suppression also 
impacts this mode of cell growth, we assessed the growth of stable shRNA Ror2 
knockdowns in soft agar (Figure 4D). Colonies greater than 150 uM in diameter were 
counted from triplicate plates in duplicate assays. Cells lacking Ror2 expression retained the 
ability to survive as single cells in soft agar, but failed to proliferate. These cells, therefore, 
failed to exhibit the anchorage independent growth of their Ror2-expressing isogenic 
counterparts, suggesting that Ror2 may play an important role in supporting cellular 
invasion in RCC tumorigenesis.
As Ror2 suppression is shown to be necessary for anchorage independent growth, we also 
asked if Ror2 expression was sufficient to induce growth. Human Ror2 (hRor2) expression 
plasmids were generated for expression in two RCC cell lines - 786-0 where Ror2 is highly 
expressed (Figure 5A) and a derivative line, WT8, where Ror2 expression is negligible 
(Figure 5B). Adding more hRor2 to the 786-0 cell line did not change anchorage 
independent growth (Figure 5C) suggesting that increasing the level of Ror2 beyond a 
threshold fails to impact this feature of tumorigenicity. However, when hRor2 was added to 
an RCC cell line that lacks robust Ror2 expression, an increase in anchorage independent 
growth was observed (Figure 5D), suggesting that Ror2 is sufficient to induce anchorage 
independent growth. Taken together, these data suggest that Ror2 expression is both 
necessary and sufficient for the anchorage independent growth characteristic of RCC.
Ror2 suppression reduces tumor growth in vivo
As our data showed that 786-0 Ror2 shRNA suppressed anchorage independent growth in 
vitro in RCC cells, we also sought to assess tumor growth in vivo. Two independently 
derived Ror2 deficient cell lines and an isogenic control shRNA cell line were injected 
orthotopically in a cohort of athymic nude (nu/nu) female mice. Macroscopically visible 
tumors were only detected in mice injected with 786-0 isogenic control cells. Additionally, 
the control cell line had significantly more tumors than the two shRNA cell lines combined. 
The histology of a control engrafted tumor with adjacent normal kidney tissue is shown in 
Figure 6A. By comparison, tumor cells derived from the Ror2 suppressed cells were present 
on microscopic evaluation of two kidneys in the vicinity of the kidney subcapsule (Figure 
6B, arrows), but failed to form clearly discrete masses. The extent of tumor growth, 
including tumors which implanted outside the area of injection, is quantified in the panel of 
Figure 6C and the average of all ten implants (in cm) was larger in the isogenic control cell 
line than in the two shRNA cell lines (Figure 6D). This experiment was replicated 
independently with xenografts grown longer than 3 months, and the results mirrored these 
findings (data not shown). MMP2 protein levels were also examined in these engrafted 
tumors. As previously shown at the transcription level, when Ror2 is expressed there is an 
abundance of MMP2 protein expression (Figure 6E, F). In tumors where Ror2 expression is 
suppressed, MMP2 protein levels are decreased (Figure 6G, H). This data confirms in vivo 
the findings of the experiments examining anchorage independent growth, validating a role 
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for Ror2 in promoting tumor cell growth independent of tumor cell survival in RCC. 
Further, this data provides concrete evidence that links Ror2 to RCC tumor development and 
places this signaling pathway as an immediate facilitator of tumor growth.
DISCUSSION
In a strategy to uncover potential signaling kinases for RCC, we have identified the 
developmentally regulated orphan kinase Ror2 as an activated tyrosine kinase in RCC 
cancer cell lines and renal tumors. Ror2 is physiologically expressed primarily on embryonic 
mesenchymal cells and developmentally expressed on migrating mesenchymal cells of the 
fetal kidney. The aberrant expression of Ror2 in human RCC tumors has not been 
specifically described to date, although evidence of active Ror2 has been observed on kinase 
arrays from glioblastoma cell lines (Stommel et al., 2007). In this study, however, for the 
first time we show that Ror2 expression was detected in the majority of human RCC tumors, 
and protein expression was confirmed at the tumor cell level. These data support the 
identification of a tumor cell intrinsic receptor tyrosine kinase, usually limited to developing 
mesenchymal cell subsets, that is detectable on the majority of renal cell carcinomas.
Ror2 expression in RCC may herald the activation of many signalling events, particularly in 
the aberrant context of a tumor cell environment. For epithelial cells to metastasize, they 
must acquire mesenchymal characteristics that permit proliferation outside of the usual 
niche. Ror2 is primarily expressed in mesenchymal cells, immediately suggesting a possible 
role for this kinase as part of the ECM remodeling process in tumor development. 
Expression of the Ror2 kinase in human tumors was found to be tightly correlated with 
genes involved at the ECM, in particular MMP2, linking this epithelially derived tumor with 
mesenchymal phenotypic markers and a potentially important transitioning event in the 
development of invasive renal cell carcinoma. Matrix metalloprotease-2 (MMP2) has 
previously been shown to be overexpressed in many metastatic cancers including RCC 
(Kurban et al., 2006; Zhang et al., 2002) and Ror2 may define an important and unique 
pathway for this process in kidney cancers (Kurban et al., 2006). MMP2, in particular 
among the MMP family, is essential for the renal tubular cell epithelial to mesenchymal 
transformation (EMT) specific to the recovery from renal tubular injury (Irwin et al., 2003). 
This process requires adaptations of the extracellular matrix as well as mechanisms of 
promoting cellular migration. Using wound healing as a surrogate for cell migration, we 
found that Ror2-suppressed cells migrated at a slower rate than their isogenic partners. As a 
critical test of tumor cell growth in a three-dimensional environment, Ror2 expression 
supported anchorage independent cell growth, an indicator of tumor cell growth and a 
critical quality of metastatic tumors. We further demonstrated that suppression of Ror2 was 
sufficient to inhibit tumor growth in xenografts, suggesting a key role in permitting the 3-
dimensional growth essential for tumor formation.
It is additionally intriguing to consider the unique embryonic origins of the kidney, in which 
the epithelial tissues are entirely derived from a mesenchymal source. The process of 
developing the excretory tubules has in fact been termed a “mesenchymal to epithelial 
transition” (Davies, 1996). The kidney is derived from the ureteric bud and the metanephric 
mesoderm (Saxen & Sariola, 1987), thus the emergence of Ror2 as a part of a 
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dedifferentiation profile may provide the embryonic signal necessary to reinact a 
mesenchymal program in malignant epithelial cells derived from the kidney. Taken together, 
these data suggest that Ror2 can play an important role in renal cell carcinoma growth 
patterns by providing tumor cells with an immature phenotype primed for invasive growth.
Further, the regulation of Wnt signaling via Wnt receptors such as Ror2 can be greatly 
influenced by the availability of Wnt ligands, Frizzled family members, and factors such as 
the secreted frizzled related protein 1, which may influence the activity of Ror2 in 
tumorigenicity (Billiard et al., 2005). It remains uncertain which specific Wnt signaling 
pathway Ror2 engages as a cancer promoting factor; thus, the identification of Ror2 as a 
feature of RCC presents a novel avenue for future integrated studies of developmental and 
cancer biology.
Ror2 activity thus defines a novel component of the signaling machinery in place to promote 
the growth of many renal tumors and may define a unique tumor subset with distinct 
pathologic or physiologic characteristics. Finally, this newly identified kinase in RCC 
provides an ideal candidate to explore as a marker of tumors with aggressive growth 
potential or as a putative target to disable tumor growth.
MATERIALS AND METHODS
Human Phospho-Receptor Tyrosine Kinase (RTK) array
A human phospho-RTK array kit (RND Systems, Minneapolis, MN) was used according to 
the manufacturer’s instruction. Phosphorylated RTKs were detected using ECL-Plus 
chemiluminescence reagents (GE, Pittsburg, PA).
Cell culture and treatments
786-0 and RCC4 cell lines, and derivatives 786-0 RC3 and WT8 (vector control transfected 
and VHL transfected clones, respectively, kindly provided by Dr. W. Kaelin, Boston, MA), 
and RCC4 2-1 (vector transfected clone, kindly provided by Dr. M.C. Simon and Dr. B. 
Keith, Philadelphia, PA), were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
with 10% fetal bovine serum (FBS), L-glutamine and non essential amino acids. The shRNA 
knockdown cells were generated by introducing commercial shRNAs in pRetroSuper (pRS) 
for Ror2 (Origene Technologies Inc, Rockville, MD), a control virus delivering pRS (empty 
vector) or a scramble short hairpin retrovirus. Puromycin selection was used to maintain the 
shRNAs. Overexpression cell lines were generated by transferring hRor2 cDNA (Origene 
Technologies Inc, Rockville, MD) into the pcDNA6/V5-HisA plasmid (Invitrogen, 
Carlsbad, CA) via SacI/XhoI restriction enzyme sites (New England BioLabs Inc, Ipswich, 
MA). The HKC line (kindly provided by Dr. L. Racusen, Baltimore, MD (Racusen et al., 
1997)) was maintained in DMEM/F12 supplemented with 10% FBS.
RT-PCR and qRT-PCR
Total RNA was prepared using Gentra Systems RNA Extraction Cell Kit (Minneapolis, 
MN). cDNA was made from 0.5μg total RNA by reverse transcriptase (RT) using oligo dT 
primers and Superscript II RT-PCR reagents (Invitrogen, Carlsbad, CA). For automated 
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TaqMan qRT-PCR, proprietary commercial FAM labeled primers were used targeting Ror2, 
MMP2, Twist1 and β-actin (Applied Biosystems, Foster City, CA) and analyzed on the 
7900H Fast Real-Time PCR System (Applied Biosystems, Foster City, CA). For RT-PCR, 
primers targeting the Ror2 CRD domain (Left: 5′ tttcaggatgattaccacgag 3′, Right: 5′ 
ctcacacttgggcagctgaa 3′) were generated. The Ror2 CRD domain PCR fragment was 
confirmed by bidirectional DNA sequencing and BLAST sequence homology analysis. 
Standard HPRT primers (Left: 5′ cctgctggattacatataagcactg 3′, Right: 5′ 
gtcaagggcatatccaacaacaaac 3′) were used to analyze the RNA integrity.
Immunoblotting
Cells were lysed in whole cell extraction buffer containing 20mM Tris, 100mM NaCl, 1 mM 
EDTA, 1% NP-40 and protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN). 
Bradford reagent was used to assess the concentration. Protein samples were separated on 
8% SDS-polyacrylamide gels and transferred to nitrocellulose (GE, Pittsburg, PA). The 
following antibodies were used to assess for expression: Monoclonal Ror2 at 1:250 (RND 
Systems, Minneapolis, MN), Polyclonal Ror2 at 1:3000 (RND Systems, Minneapolis, MN), 
Twist1 at 1:1000 (Cell Signaling Technology Inc, Danvers, MA), V5-HRP at 1:2500 
(Invitrogen, Carlsbad, CA), Ku80 at 1:2000 (Genetex Inc, San Antonio, TX) as a loading 
control (LC). Appropriate horseradish peroxidase conjugated secondary antibodies were 
used and proteins detected using ECL-Plus chemiluminescence reagents (GE, Pittsburg, 
PA).
Immunoprecipitation
500μg of cell lysates were immunoprecipitated using a polyclonal biotinylated Ror2 
antibody (RND Systems, Minneapolis, MN), Epo (N-19) nonspecific IgG goat antibody 
(Santa Cruz, Santa Cruz, CA) and a bead only control using streptavidin conjugated 
Dynabeads-280 (Invitrogen, Carlsbad, CA). Immunoblotting was performed as described 
above using monoclonal anti-Ror2 at 1:250 (RND Systems, Minneapolis, MN) and pY99 
anti-phosphotyrosine at 1:1000 (Santa Cruz, Santa Cruz, CA).
Wound Healing Assay
35,000 cells were plated in triplicate on 6-well plates and allowed to adhere overnight at 
37°C in 10% FBS media. The monolayer was then “wounded” in perpendicular directions 
with a 200ul pipet tip (forming a cross) and 2% FBS media was added. Pictures were taken 
at each of the cross junctions at 4x magnification at 0, 8, 16, and 24 hours.
Soft Agar Colony Formation Assay
0.6% bottom agar was plated onto 6-well plates. 10,000 cells were plated in triplicate, 
placed at 37°C overnight and covered with 0.2mL RCC media. Colonies were allowed to 
form over 3-4 weeks and then stained with 2mg/mL MTT (Sigma-Aldrich, St. Louis, MO) 
for 1-4hrs. Images were taken at 10x magnification. Black bar represents 67.3μm.
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A modified MTT assay (Promega, Madison, WI) was used to assess cell viability. 5,000 
cells were plated with 50uL selection media for 5 days. The MTT dye containing the 
tetrazolium salt was added according to manufacturer instructions and absorbance measured 
at 570nm.
Doubling Time Assay
300,000 cells were plated and after 96hrs, the total number of cells was counted. This 
process was repeated 10 times and the doubling time calculated.
Immunohistochemistry and Immunofluorescence
RCC tumor blocks were obtained from the UNC Tissue Procurement Facility with approval 
by the institutional review board (IRB) and serially sectioned onto unprepared glass slides. 
The first section was stained with hematoxylin and eosin (H&E) for tumor verification, and 
a subsequent section probed with a primary mouse anti-human Ror2 monoclonal antibody 
(generated by Drs. Mikels and Nusse). Detection was performed according to the 
instructions of the TSA™-plus Fluorescien System (NEL 741001 KT from PerkinElmer 
Labs, Inc, Waltham, MA). Slides were mounted with Vectashield (H-1200, Vector 
Laboratories, Burlingame, CA) and imaged using fluorescence microscopy at 20X 
magnification. Black bar represents 34uM. Immunohistochemical stain on human fetal 
kidney sections acquired through an IRB-approved protocol was performed using the same 
Ror2 monoclonal antibody. Standard antigen unmasking procedures were used and protein 
was detected using di-amino benzidine.
Xenograft Analysis
500,000 cells were injected orthotopically under the kidney capsule in a cohort of athymic 
nude (nu/nu) female mice and aged 2.5 or 3 months. The xenografted tumors were formalin 
fixed, paraffin embedded and tissue blocks were serially sectioned onto unprepared glass 
slides. Xenografted tumors were stained with hematoxylin and eosin (H&E) for tumor 
verification. The slides were immunostained with MMP2 antibody 3158 (Abcam Inc, 
Cambridge, MA) and detected as above.
Microarray Analysis
Fresh frozen tumors from the UNC Tissue Procurement Facility tumor bank (1994-2007) 
were used for these studies. Total mRNA was prepared as described above, incorporating a 
Rotor-Stator for tissue homogenization. Quantitation was performed by NanoDrop 
(NanoDrop Technologies, Wilmington, DE). RNA quality check, amplification, labeling, 
and hybridization was performed by the UNC Genomics Core Facility. Two-color 
hybridization was performed, with a modified reference human mRNA derived from the 
Stratagene Universal Human Tumor Reference RNA (kindly provided by Dr. C. Perou, 
Chapel Hill, NC).
Raw data was derived using Agilent feature extraction software, and results were expressed 
as a Log (2)-transformed ratio between tumor and control mRNA. Three-way comparison 
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was performed using Significance Analysis of Microarrays (SAM) version 3.01 (Tusher et 
al., 2001) for Supplementary Figure 2. Duplicate genes were removed, targets were median 
centered and complete linkage analysis was performed with Pearson’s Correlation with 
Cluster 3.0. For Figure 3, quantitative analysis of data according to Ror2 gene expression 
was performed using SAM. Genes with a false discovery rate <5% were then used for 
average linkage analysis with Cluster 3.0. Gene set analysis was also performed in SAM 
according to Ror2 gene expression values, using a cutoff of FDR=0. Gene sets analyzed 
were from Erin Segal or the MSigDB collection at the Broad Institute.
Statistical Analysis
The standardized cycle threshold (cT) values were fit with a one-way ANOVA model with 
the experimental variable of interest (Ror2, EGLN3, MMP2, etc) as the fixed effect. To 
verify the one-way ANOVA model, a nonparametric statistical procedure, Kruskal-Wallis 
test, was performed to compare the standardized cT among the cell lines. Error bars are 
shown as standard error of the mean (SEM).
Ror2 expression was evaluated across RCC tumor histologies using a Student’s T test to 
assign p values as shown. Because clear cell tumors are more common than other 
histologies, the difference in sample size is reflected in the standard deviations using an 
adjustment to account for unequal variances. A non-parametric Wilcoxon Rank Sum 
procedure was performed to confirm the significant result found using the parametric two 
sample t-test.
Supplementary Material
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Figure 1. Human RCC tumors express Ror2
A. Human Phospho-RTK array screen for activated kinases in RCC. Utilizing a phospho-
RTK array, 42 RTKs were screened for phosphorylation in RCC using the 786-0 RC3 cell 
line. Activated kinases were identified using an HRP-conjugated pan-phosphotyrosine 
antibody. From this screen, one novel RTK identified was Receptor Tyrosine Kinase-like 
Orphan Receptor 2 (Ror2). Additional spots demonstrating positive identification include a 
kinase known to be activated in RCC cells (EGFR) and negative control spots (Goat IgG).
B. RT-PCR of archival human tumor samples shows mRNA expression of Ror2. Nineteen 
(19) archival tumor samples from the UNC Tumor Bank (1994-2004) were amplified with 
primers against the CRD domain of Ror2 (HPRT gene used as a control to assess quality of 
RNA). Direct sequencing of the PCR product confirmed the product as Ror2. Representative 
examples of Ror2 expression seen in RCC tumors are shown. A tabular distribution of 
tumors expressing a Ror2 transcript is shown for the individual RCC histological subtypes.
C. Ror2 is expressed in fetal kidney tissues. Left panel, H&E stain of fetal kidney, Middle 
panel, Ror2 expression detected by immunohistochemistry on primitive migrating 
mesenchymal cells, Right panel, CD117 is used as a negative control for staining specificity 
in the fetal kidney and (expected to be negative as shown) is a control for staining specificity 
for the secondary antibody.
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Figure 2. Immunofluorescence detects Ror2 in human RCC tumors
Three individual RCC tumors were stained to determine the cellular expression of Ror2. 
H&E of the 3 tumors verifies clear cell histology. Two tumors were selected having high 
expression of Ror2 transcript (+), and a third tumor identified as having undetectable levels 
of Ror2 transcript (-) was used to verify antibody specificity. An Ror2 antibody was used to 
assay for Ror2 expression in the RCC tumors. Top and middle panels show that Ror2, a 
transmembrane cell surface receptor, is mainly expressed in the cell surface or cytoplasm, 
with no detectable protein in the control tumor in the bottom panel. Control panels show 
negative staining in the no primary control. DAPI is included for both primary and no 
primary antibody stained sections to demonstrate nuclear staining. All pictures were taken at 
20X and the black bar represents 34 uM.
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Figure 3. Microarray analysis of RCC tumors defines a tumor genetic phenotype
Tumor mRNA from 40 RCC tumors were analyzed by Agilent 4×44K gene expression 
microarray and separated into groups based on their Ror2 expression. SAM analysis was 
performed to identify differentially expressed genes, and the most significant in (A) all 
histologies (FDR <0.045) and (B) clear cell only histology (FDR<0.0388) were analyzed by 
two-way clustering.
C. Ror2 (+) RCC tumors have increased mRNA expression of genes involved at the ECM. 
Quantitative RT-PCR analysis of 2 Ror2 (-) and 2 Ror2 (+) human RCC tumors were 
analyzed to verify microarray expression. Transcript values are normalized to β-actin RNA 
internal standard and are shown relative to an Ror2 (-) tumor (Tumor A). Error bars 
represent SEM. Significant differences were observed in Twist1 (*p<0.001) and MMP2 
(**p<0.0001) in the Ror2 (+) tumors (*p<0.001) compared to Ror2 (-) tumor (Tumor A), p-
values are based on cT values.
D. Table showing the significant gene set list with corresponding genes involved at the ECM 
that clustered with Ror2 expression. Tumor mRNA were analyzed by multiclass comparison 
using SAM, and the resulting Ror2 cluster was further analyzed for over-represented gene 
categories using the Expression Analysis Systematic Explorer (EASE) (Hosack et al., 2003). 
Genes from the three most tightly associated ontogenies are listed in the table.
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Figure 4. Ror2 expression directs MMP2 expression, anchorage independent growth and 
invasive potential in vitro
A. Ror2 expression is suppressed in 786-0 cells by shRNA. Whole cell protein extracts from 
RCC cells (786-0) were infected with a scramble short hairpin retrovirus, a pRS control 
virus or Ror2 short hairpin retroviruses and immunoblotted with polyclonal Ror2 antibody, 
Twist1 antibody or Ku80 antibody as a loading control (LC).
B. MMP2 expression is suppressed when Ror2 levels are knocked down. Quantitative RT-
PCR analysis of two 786-0 Ror2 knockdown cell lines demonstrates MMP2 suppression 
coordinate with the degree of suppression of Ror2. Significant differences were observed in 
MMP2 (**p<0.001 for both comparisons) in the 786-0 Ror2 suppressed cell lines compared 
to the Ror2 expressing cell lines (**p<0.001 for both comparisons). Transcript values are 
normalized to β-actin RNA internal standard and are shown relative to 786-0 scramble RNA. 
Error bars represent SEM.
C. Ror2 knockdown decreases cell migration. RCC cells (786-0) infected with a control 
virus pRS or Ror2 short hairpin RNA retroviruses were plated and allowed to grow 
overnight. Cells were scratched and the length of the scratch was observed for both 0 hr and 
16hr timepoints (left). Significant differences were observed when comparing the % 
invasion of the Ror2 knockdown cell lines compared to the empty vector pRS control (right) 
- (**p<0.0001, *p=0.009). Error bars represent SEM.
D. Ror2 knockdown inhibits anchorage independent growth. RCC cells (786-0) infected 
with a scramble short hairpin RNA retrovirus, a control virus pRS or Ror2 short hairpin 
RNA retroviruses were allowed to grow in soft agar over a period of 3-4 weeks. Ror2 
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knockdown cells have inhibited growth in comparison to the scramble short hairpin 
retrovirus and the empty vector pRS control. Multicellular colonies >150 uM were counted 
from triplicate plates. Data shown is from the combination of two representative 
experiments (**p<0.0001). Error bars represent SEM. Inset - Cells were stained with MTT 
dye, and pictures taken at 10x magnification. Black bar represents 67.3 um.
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Figure 5. Ror2 overexpression enhances anchorage independent growth in vitro
A. Ror2 expression is increased in 786-0 cells with an overexpression plasmid. RCC cells 
(786-0) were transfected with control plasmid pcDNA6 or hRor2 cDNA and immunoblotted 
with polyclonal Ror2 antibody, a V5 antibody or Ku80 antibody as a loading control (LC).
B. Ror2 expression is amplified in the 786-0 derivative cell line WT8, a clone expressing a 
VHL cDNA which expresses reduced levels of Ror2. The RCC cell line WT8 was 
transfected with a control plasmid pcDNA6 or hRor2 cDNA and immunoblotted with 
polyclonal Ror2 antibody, a V5 antibody or Ku80 antibody as a loading control (LC). Panel 
A and B represent a contiguous blot with intervening lanes removed.
C. An increase in Ror2 expression in Ror2 expressing cells does not affect anchorage 
independent growth. RCC cells with high levels of Ror2 already expressed (786-0) 
transfected with a control plasmid pcDNA6 or hRor2 cDNA were allowed to grow in soft 
agar over a period of 3-4 weeks. Multicellular colonies >150 uM were counted from 
triplicate plates. An increase in Ror2 expression did not change colony growth. Data shown 
is from two representative experiments.
D. Ror2 overexpression increases anchorage independent growth in cells lacking Ror2 
expression. RCC cells lacking high level of expression of Ror2 (WT8) transfected with a 
control plasmid pcDNA6 or hRor2 cDNA were allowed to grow in soft agar over a period of 
3-4 weeks. Multicellular colonies >150 uM were counted from triplicate plates. Ror2 
overexpression cells displayed enhanced growth in comparison to the control empty vector 
pcDNA6. Data shown is from one representative experiment (p=0.079).
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Figure 6. Ror2 suppression reduces tumor growth in vivo
Two independent shRNA cell lines were injected orthotopically under the kidney capsule of 
athymic nude mice, compared to 786-0 pRS control cells.
A. Histology of control engrafted tumor with adjacent normal kidney tissue is shown.
B. H&E of the kidney surface demonstrated that Ror2-suppressed engrafted tumor cells 
were present in the vicinity of the subcapsule microscopically but failed to form distinct 
tumors.
C. Macroscopically visible tumors were only detected in mice injected with 786-0 pRS 
control cells. Macroscopic and microscopic evidence of tumor cells was tabulated, 
demonstrating significantly more tumors identified in the control cell implanted mice than 
those implanted with either of the two Ror2 shRNA cell lines.
D. Average tumor diameter of each implant from the 786-0 pRS control cell line and the two 
Ror2 shRNA cell lines (in cm).
E. The control engrafted tumor, 786-0 pRS, displays increased levels of MMP2 as 
determined by immunohistochemistry.
F. Control panel for 786-0 pRS shows negative staining in the no primary control.
G. The Ror2-suppressed engrafted tumor, 786-0 shRor2.1, has diminished levels of MMP2 
expression compared to the empty vector control, 786-0 pRS.
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H. Control panel for 786-0 shRor2.1 shows insignificant background staining in the no 
primary control.
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